SPRO — Spero Therapeutics, Inc.
Is SPRO overbought or oversold? Here is the current MarketMoodz read.
Spero Therapeutics, Inc. (SPRO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.95. The rating moved from Neutral to Oversold on November 14, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.95
- Last changeMoved from Neutral to Oversold on November 14, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Spero Therapeutics, Inc. (SPRO) is a small, clinical-stage biopharma with limited public disclosures in the provided data. The company likely faces typical early-stage biotech challenges: cash burn, funding uncertainty and binary clinical/regulatory outcomes. Current sector dynamics favor large-cap pharma and defensive flows, and convertible-debt/dilution pressures in the biotech space increase downside risk for mid-/small-cap issuers. Absent near-term positive clinical news, partnering activity, or clear financing visibility, downside volatility and dilution remain the dominant near-term scenarios, while any positive data or strategic transaction would materially change the outlook.
Key factors
- Small-cap clinical-stage biopharma with limited public information available in this dataset
- Likely elevated cash burn and funding needs typical of clinical-stage biotech issuers
- Sector flows favor large-cap pharma and defensive names, reducing investor appetite for speculative small biotechs
- Convertible-debt / dilution pressure in the sector increases probability of equity issuance or adverse investor hedging
- No material recent company-specific disclosures or social sentiment signals in the provided input to support near-term upside
Risks
- Positive clinical-data readout, surprise partnering/licensing deal, or takeover could drive a sharp upward revaluation
- Equity or convertible financings that dilute existing shareholders and depress per-share value
- Regulatory setbacks or trial failures that could rapidly erode valuation
- Overall market risk-off episodes that disproportionately hit penny/clinical-stage biotech names
- Biotech-specific volatility and low liquidity can amplify price moves and create wide bid-ask spreads
See today's live rating, score and targets
Members see the live hourly rating for SPRO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.